Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Moderate Buy consensus from five analysts (four buys, one sell) with an average 12‑month target of $8.50, while Weiss Ratings has reiterated a "sell (d-)" on the shares.
• Shares opened at $1.91 with a market cap of $81.46M, trade below their 50‑ and 200‑day moving averages and carry a negative P/E (-3.13); the company beat Q1 EPS estimates (‑$0.11 vs. ‑$0.14) but is forecast to post about ‑0.54 EPS for the year.
• Gain is a clinical‑stage biotech leveraging the AlphaTarget allosteric‑modulation platform, with lead clinical candidate GT‑022 being developed for Gaucher disease.

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has received a consensus rating of "Moderate Buy" from the five research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $8.50.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Gain Therapeutics in a report on Friday, April 10th.

Gain Therapeutics Price Performance

NASDAQ GANX opened at $1.91 on Thursday. The company has a 50 day simple moving average of $2.16 and a 200-day simple moving average of $2.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.63 and a quick ratio of 6.63. The firm has a market capitalization of $81.46 million, a price-to-earnings ratio of -3.13 and a beta of 0.15. Gain Therapeutics has a 52-week low of $1.41 and a 52-week high of $4.34.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. Equities research analysts predict that Gain Therapeutics will post -0.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Millennium Management LLC acquired a new stake in shares of Gain Therapeutics in the fourth quarter valued at $45,000. Engineers Gate Manager LP acquired a new stake in Gain Therapeutics in the fourth quarter worth about $47,000. Wealthspire Advisors LLC acquired a new stake in Gain Therapeutics in the fourth quarter worth about $54,000. Sprott Inc. acquired a new stake in Gain Therapeutics in the fourth quarter worth about $39,000. Finally, Commonwealth Equity Services LLC acquired a new position in shares of Gain Therapeutics during the 4th quarter worth about $41,000. 11.97% of the stock is owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc NASDAQ: GANX is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain's lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.